ALT
Altimmune, Inc.Company Information
- Company Name
- Altimmune, Inc.
- CIK
- CIK0001326190
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ALT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ALT
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-04-06
- Last sale
- 2024-08-19
- Shares purchased (TTM)
- 90,227
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 68,737,650
- Shares outstanding
- 124,461,818
- Ownership
- 55.23%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 16.72%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 63 | 98 | 44 | 61 | 183 | 49 | 37 | 31 | 57 | 79 | 135 | 87 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Short Term Investments | 263 | 234 | 230 | 150 | - | 101 | 95 | 108 | 108 | 103 | 63 | 54 | ||||||
| Accounts Receivable Gross Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Accounts And Other Receivables Net Current | 3 | 2 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | - | ||||||
| Prepaid Expense And Other Assets Current | 5 | 1 | 3 | 4 | 4 | 3 | 2 | 3 | 3 | 3 | 7 | 8 | ||||||
| Assets Current | 335 | 335 | 278 | 217 | 188 | 155 | 137 | 146 | 171 | 188 | 210 | 153 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 192 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | - | - | - | - | - | - | - | - | - | - | - | 12 | ||||||
| Other Assets Noncurrent | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | ||||||
| Assets | 527 | 336 | 280 | 218 | 190 | 157 | 139 | 148 | 173 | 188 | 211 | 167 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 2 | 3 | 5 | 1 | 1 | 0 | 1 | 3 | 4 | 2 | 3 | ||||||
| Liabilities Current | 13 | 11 | 15 | 13 | 9 | 10 | 10 | 9 | 15 | 11 | 12 | 12 | ||||||
| Other Long Term Debt Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 4 | ||||||
| Liabilities Noncurrent | - | - | - | - | - | 5 | 5 | 6 | 6 | 4 | 4 | - | ||||||
| Long Term Debt Noncurrent | 35 | 35 | 34 | 14 | 14 | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 6 | 6 | 6 | 6 | 5 | - | 5 | - | - | - | - | - | ||||||
| Liabilities | 53 | 52 | 55 | 33 | 29 | 15 | 16 | 14 | 21 | 15 | 17 | 16 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,175 | 961 | 879 | 813 | 770 | 728 | 690 | 676 | 673 | 669 | 665 | 590 | ||||||
| Retained Earnings Accumulated Deficit | -695 | -672 | -649 | -622 | -603 | -581 | -561 | -538 | -515 | -491 | -466 | -435 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -6 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | ||||||
| Stockholders Equity | 474 | 284 | 225 | 186 | 161 | 142 | 124 | 133 | 153 | 173 | 194 | 150 | ||||||
| Liabilities And Stockholders Equity | 527 | 336 | 280 | 218 | 190 | 157 | 139 | 148 | 173 | 188 | 211 | 167 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 194 | 130 | 111 | 96 | 85 | 78 | 72 | 71 | 71 | 71 | 71 | 53 | ||||||
| Shares Outstanding | 194 | 130 | 111 | 96 | 85 | 78 | 72 | 71 | 71 | 71 | 71 | 53 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAltimmune, Inc. (ALT) — SEC Financial Statements & Analysis
Altimmune, Inc. (ALT) is a pharmaceutical preparations company, incorporated in DE. Altimmune, Inc. trades on Nasdaq as: ALT. Altimmune, Inc. (ALT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Altimmune, Inc. carries a market cap of $563.75M, a P/E ratio of -6.14x, a P/B ratio of 1.19x, a P/S ratio of 18185.45x, an enterprise value of $535.44M, and an EV/EBITDA multiple of -5.35x. On profitability, it posts a gross margin of 108.29%, an operating margin of -323306.45%, a net margin of -296000.00%, a Return on Equity (ROE) of -28.87%, a Return on Assets (ROA) of -25.58%, and a Return on Invested Capital (ROIC) of -45.38%. Per share, it reports EPS of $-0.49, diluted EPS of $-0.49, free cash flow per share of $-0.41, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 55.00% year-over-year, net income growth of 4.57% year-over-year, and EPS growth of -54.05% year-over-year. On the balance sheet, it maintains a current ratio of 26.78x, a quick ratio of 26.37x, working capital of $322.31M, a debt-to-equity ratio of 0.11x, a debt ratio of 0.1, an interest coverage ratio of -28.34x, free cash flow of $-76.56M (TTM), and net debt of $-28.31M. Figures sourced from SEC EDGAR.
- Market Cap
- $563.75M
- P/E TTM
- -6.14x
- EPS TTM
- $-0.49
- P/B TTM
- 1.19x
- ROE TTM
- -28.87%
- ROA TTM
- -25.58%
- Debt To Equity
- 0.11x
- Free Cash Flow TTM
- $-76.56M
- Net Revenue TTM Growth 1Y
- 55.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Altimmune, Inc. in?
Altimmune, Inc. (ALT) operates in the Pharmaceutical Preparations industry.
What exchange does ALT trade on?
Altimmune, Inc. (ALT) trades on the Nasdaq.
Where is Altimmune, Inc. incorporated?
Altimmune, Inc. is incorporated in DE.
When was Altimmune, Inc. (ALT)'s most recent SEC filing?
Altimmune, Inc. (ALT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is ALT's market cap?
Altimmune, Inc. (ALT) has a market capitalization of $563.75M as of 2026-06-30.
What is ALT's EPS (earnings per share)?
Altimmune, Inc. (ALT)'s trailing twelve month EPS is $-0.49 as of 2026-06-30.
What is ALT's ROE (return on equity)?
Altimmune, Inc. (ALT)'s trailing twelve month Return on Equity (ROE) is -28.87% as of 2026-06-30.
What is ALT's ROA (return on assets)?
Altimmune, Inc. (ALT)'s trailing twelve month Return on Assets (ROA) is -25.58% as of 2026-06-30.
What is ALT's ROIC (return on invested capital)?
Altimmune, Inc. (ALT)'s trailing twelve month Return on Invested Capital (ROIC) is -45.38% as of 2026-06-30.
What is ALT's EV/EBITDA?
Altimmune, Inc. (ALT)'s trailing twelve month EV/EBITDA is -5.35x as of 2026-06-30.